Adding STING to the Tale of Oncolytic Virotherapy

Trends in Cancer

Volumn 2, Issue 2, 2016, Pages 67-68

  Thorne, Steve H ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

HSV; oncolytic virus; STING; vaccinia

Indexed keywords

STIMULATOR OF INTERFERON GENE; UNCLASSIFIED DRUG; VIROTHERAPY AGENT;

ADAPTIVE IMMUNITY; CARCINOGENESIS; COLON CANCER; DNA VIRUS; GENE MUTATION; HUMAN; IMMUNE RESPONSE; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84959278572     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.01.002     Document Type: Short Survey

References (7)

1. T. Xia, and et al. Deregulation of STING signaling in colorectal carcinoma constrains DNA-damage responses and correlates with tumorigenesis Cell Rep. 2015 10.1016/j.celrep.2015.12.029 Published online December 31, 2015
2. H. Ishikawa, and G.N. Barber STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling Nature 455 2008 674 678
3. J. Ahn, and et al. STING manifests self DNA-dependent inflammatory disease Proc. Natl. Acad. Sci. U.S.A. 109 2012 19386 19391
4. S.R. Woo, and et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors Immunity 41 2014 830 842
5. J. Heo, and et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Nat. Med. 19 2013 329 336
6. R.H.I. Andtbacka, and et al. OPTiM: a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma J. Clin. Oncol. 31 Suppl. 2013 LBA9008
7. J. Fu, and et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade Sci. Transl. Med. 7 2015 283ra52